Synapse

← EJC Skin Cancer

Papers in EJC Skin Cancer

Page 2 · newest first

  1. Outcomes and prognostic factors of immune checkpoint inhibitor resumption in advanced melanoma, results from the MIRROR (melanoma immunotherapy resumption: Retrospective outcomes review) multicenter real-world studyEJC Skin Cancer · 2026
  2. Metastatic melanoma involving the uterine corpus: Diverse patterns of involvement and diagnostic pitfalls in a three-case seriesEJC Skin Cancer · 2026
  3. SUPRAME: A Phase 3 trial evaluating anzutresgene autoleucel (anzu-cel, IMA203) PRAME-directed T-cell receptor T-cell therapy vs investigator’s choice in previously treated advanced cutaneous melanomaEJC Skin Cancer · 2026
  4. Granulomatous Mycosis Fungoides: A 15-Year Differential Diagnostic ChallengeEJC Skin Cancer · 2026
  5. Diffuse Large B-Cell Lymphoma with Oropharyngeal Involvement Developing on the Background of Hermansky Pudlak Syndrome Type 2: A Case ReportEJC Skin Cancer · 2026
  6. Telangiectasia macularis eruptiva perstans in adults: a skin marker of clonal mast cell diseaseEJC Skin Cancer · 2026
  7. Efficacy of combined BRAF-MEK inhibitor second-line therapy in patients with non-resectable or metastatic BRAFV600-positive melanoma after prior immunotherapy: A retrospective EUMelaReg multicenter studyEJC Skin Cancer · 2025
  8. Switch to every-other-day sonidegib dose reduction schedule in advanced basal cell carcinoma: a multicenter retrospective observational study on effectiveness and safetyEJC Skin Cancer · 2025
  9. The impact of a SmartPhone applicatiOn for skin cancer risk assessmenT on the healthcare system (SPOT-study): A randomized controlled trialEJC Skin Cancer · 2025
  10. Neoadjuvant and adjuvant therapy for locally advanced cutaneous squamous cell carcinomaEJC Skin Cancer · 2025
  11. Prognostic and predictive importance of body mass index and type 2 diabetes in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanomaEJC Skin Cancer · 2025
  12. Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab vs placebo in resected stage III melanomaAustralasian Journal of Paramedicine · 2025
  13. Comparative analysis of international melanoma guidelinesEJC Skin Cancer · 2025
  14. Machine learning algorithms using dermatoscopy for the prediction of melanoma prognosis: A narrative review of the literatureEJC Skin Cancer · 2025
  15. Selecting first-line immunotherapy in advanced melanoma: Current evidence on efficacy across diverse patient populationsEJC Skin Cancer · 2025
  16. Cutaneous adverse events of pan-RAF inhibitor naporafenib (LXH254) containing drug combinations in NRAS-mutant metastatic melanomaEJC Skin Cancer · 2025
  17. Crosstalk between CLL and cutaneous T-cell lymphoma: MIF-CD74 axis and dysregulated inflammatory signalingEJC Skin Cancer · 2025
  18. Clinical characteristics and treatments of Merkel cell carcinoma in Japan: A multi-center retrospective studyEJC Skin Cancer · 2025
  19. Unveiling cutaneous adenosquamous carcinoma: A systematic review and case analysis of a rare cutaneous malignancyEJC Skin Cancer · 2025
  20. Prognostic significance of sentinel node tumor burden in Merkel Cell CarcinomaEJC Skin Cancer · 2025
  21. Validation of the MIA and MSKCC Nomograms for Sentinel Node Positivity Prediction in a Spanish Melanoma CohortEJC Skin Cancer · 2025
  22. Italian expert opinion on the treatment of mycosis fungoides with chlormethine gel: Results of a Delphi consensusEJC Skin Cancer · 2025
  23. Treatment of dermatofibrosarcoma protuberans with fixed Mohs' micrographic surgery: A French cohort prospective studyEJC Skin Cancer · 2025
  24. Molecular analyses in melanocytoma diagnosis and risk progression assessmentEJC Skin Cancer · 2025
  25. BRAF/MEK inhibition following immune checkpoint inhibitors promotes antitumor immunity associated with expansion of progenitor-exhausted CD8⁺ T cellsEJC Skin Cancer · 2025
  26. The Occupational Skin Cancer Multi-Stakeholder Summit JourneyEJC Skin Cancer · 2025
  27. Tunlametinib for NRAS-mutated pediatric melanoma arising from a giant congenital melanocytic nevus: A rapidly progressive caseEJC Skin Cancer · 2025
  28. Hazard rates and implications for follow-up schedules of melanoma patients with 0.8–1.0 mm tumor thickness: An analysis of the German Central Malignant Melanoma Registry in 12,132 patientsEJC Skin Cancer · 2025
  29. Retrospective study of definitive therapy for head and neck mucosal melanoma: The RESUME studyEJC Skin Cancer · 2025
  30. Challenges in developing a digital pathology consultation network: insights from the MELCAYA experienceEJC Skin Cancer · 2025
  31. Comparing Mohs micrographic surgery with wide local excision for the surgical treatment of dermatofibrosarcoma protuberans: A Dutch retrospective cohort studyEJC Skin Cancer · 2025
  32. Evaluating perineural invasion severity in head and neck cutaneous squamous cell carcinomas to refine prognostic accuracy: A retrospective case-control studyEJC Skin Cancer · 2025
  33. Locally advanced basal cell carcinoma in real life: Analysis of a cohort of 452 patients treated with systemic therapy from the CARADERM databaseEJC Skin Cancer · 2025
  34. Cross-method comparison for BRAF p.V600 mutation cfDNA testing in Melanoma: BRAFI studyEJC Skin Cancer · 2025
  35. The evolving role of immune checkpoint inhibitors in cutaneous squamous cell carcinoma: Across the disease spectrumEJC Skin Cancer · 2025
  36. Neoadjuvant and adjuvant therapy for locally advanced cutaneous squamous cell carcinomaEJC Skin Cancer · 2025
  37. Melanoma-specific risk associated with hormone replacement therapy and fertility treatments: A narrative review and a clinical guideEJC Skin Cancer · 2025
  38. Efficacy of immune checkpoint inhibitors in advanced mucosal melanoma: A systematic review and meta-analysisEJC Skin Cancer · 2025
  39. Outcomes from early discontinuation of immune checkpoint inhibitor therapy following response in patients with advanced cutaneous squamous cell carcinomaEJC Skin Cancer · 2025
  40. Impact of osteoprotective therapies on the efficacy of immune checkpoint inhibition in melanoma patients – A multicentre study from the prospective skin cancer registry ADORegEJC Skin Cancer · 2025
  41. Potential biomarkers of skin cancer diagnosis revealed through volatile metabolomics – A prospective research studyEJC Skin Cancer · 2025
  42. The TRIAGE and ASSIST scan: A new concept in 3D total body imaging for early melanoma detectionEJC Skin Cancer · 2025
  43. Quality of Life (QoL) and care pathway in patients with durable response to Immune Checkpoint Inhibitors (ICI-DR) for advanced or metastatic melanoma: QUALICI studyEJC Skin Cancer · 2025
  44. Melanocytic nevi and sun exposure as major risk factors for CM. Hospital-based study in LithuaniaEJC Skin Cancer · 2025
  45. Patterns of systemic treatment for melanoma: An insight on trends and costs between 2019–2023 from the English systemic anti-cancer therapy national databaseEJC Skin Cancer · 2024
  46. Adjuvant and neoadjuvant immunotherapy for acral and mucosal melanomaEJC Skin Cancer · 2024
  47. Solar elastosis correlates with high tumor mutation burden and better 5-year disease-specific survival in patients with stage II/III melanomaEJC Skin Cancer · 2024
  48. Real-World efficiency of pembrolizumab in metastatic melanoma patients following adjuvant anti-PD1 treatmentEJC Skin Cancer · 2024
  49. Long-term control with immunotherapy and aggressive re-irradiation for basal cell carcinoma metastatic to the vertebra: A case report and literature review of rare osseous metastasisEJC Skin Cancer · 2024
  50. Sex-specific and sex hormonal-related differences in melanoma microenvironmentEJC Skin Cancer · 2024